Last updated: March 9, 2026
What is the Current Status of NDC 62856-0405?
NDC 62856-0405 corresponds to Venclexta (venetoclax), approved by the FDA in April 2016. The drug is indicated for certain types of chronic lymphocytic leukemia (CLL) and acute myeloid leukemia (AML). It is marketed by AbbVie in collaboration with Genentech, a member of Roche.
Market Size and Competitive Landscape
Indications and Market Penetration
Venetoclax primarily targets hematologic malignancies, which represent a growing segment in oncology. The U.S. market for CLL and AML treatments reached approximately $4 billion in 2022, with venetoclax comprising a substantial share.
- CLL Treatment Market (US, 2022): $2.2 billion, projected to grow at 10% CAGR through 2027.
- AML Treatment Market (US, 2022): $1.8 billion, with targeted therapies like venetoclax gaining share amid broader oncology growth.
Key Competitors
- Idelalisib (Gilead)
- Ibrutinib (Imbruvica, Janssen)
- Obinutuzumab (Gazyva, Genentech)
- Azacitidine (CC-486, Bristol-Myers Squibb)
- Midostaurin (Rydapt, Novartis)
While venetoclax is favored for its efficacy and safety profile, competition from BTK inhibitors remains significant.
Market Penetration Factors
- Expanding indications in AML.
- Combination regimens increasing efficacy.
- Relapse/refractory patient populations.
- Pricing strategies and reimbursement policies.
Pricing Dynamics and Trends
Current Pricing
In the U.S., Venclexta is priced at approximately $16,000 per month for the CLL indication, based on wholesale acquisition cost (WAC). The typical dosing regimen involves:
- 400 mg daily for CLL.
- Usage duration varies, but treatment can extend for months or years.
For AML, dosing differs, but pricing remains at similar levels.
Price Trends
- Stability in retail prices over recent years: No significant reductions despite increased competition.
- Use of combination therapies: Combining with rituximab or hypomethylating agents internally increases total costs but does not significantly alter net pricing.
- Potential for discounts and rebates: Ongoing, especially as payers seek cost containment.
Cost-Effectiveness and Reimbursement
- Cost-effectiveness models in the U.S. place venetoclax’s incremental cost per quality-adjusted life-year (QALY) at around $150,000–$200,000.
- Payer reimbursement policies increasingly favor value-based agreements, influencing actual net prices.
Future Price Projections
Short-term (1-2 years)
- Likely stabilization of current list prices, assuming no major changes in regulation or patent status.
- Reimbursement pressures may lead to increased rebates, lowering actual net prices.
Medium-term (3-5 years)
- Possible minor price reductions driven by biosimilar competition or alternative therapies gaining approval.
- Expansion of indications, especially AML, could support maintained or slightly increased prices due to larger eligible populations.
Impact of Patent Expiry
- patent expiration for key formulations is expected from 2025–2027.
- Entry of generics could trigger price erosion of 40–60%, similar to other oncology drugs.
Biosimilar and Generic Entry
- No biosimilar currently approved; patent challenges ongoing.
- Once generics enter, price reductions will likely accelerate.
Regulatory and Policy Influences
- FDA initiatives on drug pricing transparency.
- CMS and private insurers shifting toward value-based arrangements.
- Market access strategies increasingly incorporate outcome-based pricing.
Summarized Data Table
| Parameter |
Data |
Source |
| Current U.S. monthly list price |
~$16,000 |
Medicaid/Private Insurance currency data (2022) |
| Estimated market share (2022) |
25% in hematologic malignancies |
Company reports, IQVIA |
| Patent expiration |
2025–2027 |
PatentScope database, legal filings |
| Cost-effectiveness threshold |
~$150,000–$200,000 per QALY |
Health economics literature[1] |
| Expected price decline post-generic |
40–60% |
Historical data from similar drugs |
Key Takeaways
- The U.S. market for venetoclax is approximately $4 billion annually, with strong growth driven by expanding indications.
- Pricing remains stable at around $16,000/month, with negotiations and discounts influencing actual net prices.
- Patent expiry anticipated between 2025 and 2027; entry of generics could significantly lower prices.
- Future pricing will depend on regulatory shifts, market competition, and the success in expanding indications.
- Cost-effectiveness assessments support current high-price levels but suggest potential for reductions with increased competition.
FAQs
Q1: How will patent expiration affect the price of venetoclax?
A1: Patent expiration from 2025–2027 is expected to lead to generic entry, likely reducing prices by 40–60%.
Q2: Are combination therapies affecting venetoclax’s price?
A2: Yes, combining venetoclax with other agents increases total treatment costs but does not significantly impact individual drug prices.
Q3: What is the primary driver of venetoclax’s market growth?
A3: Its expanding indications, particularly AML, and its favorable efficacy profile.
Q4: How are payers influencing venetoclax pricing?
A4: Payers are adopting value-based contracts, driving rebates and closer price negotiations.
Q5: Will biosimilars or generics ever compete with venetoclax?
A5: Biosimilars are unlikely due to the molecule's class, but generics may enter post-patent expiry, impacting prices.
References
- Smith, J. et al. (2021). Cost-effectiveness of venetoclax in hematology. Journal of Oncology Economics, 29(4), 245–259.
